Things are looking up for 23andMe. Right off a fresh $115 million cash infusion, the Food and Drug Administration is giving the direct-to-consumer DNA company the green light to include health and carrier traits, along with ancestry reports. This was not the scenario two years ago when the FDA put a moratorium on 23andMe’s ability to provide any health information associated… Read More
Source: Tech Crunch